SLC5A2 and chronic kidney disease: Innovation in drug development often begins with foundational academic research, where breakthroughs sometimes arise serendipitously, as in the case of sodium-glucose cotransporter 2 inhibition and glucagon-like peptide-1 receptor agonism for chronic kidney disease (CKD) [3, 4].